Poster Abstract Session:
047. Clinical: Skin and Soft Tissue
Thursday, October 5, 2017: 12:30 PM-2:00 PM
Room: Poster Hall CD

Risk Factors for Pseudomonas aeruginosa in Diabetic Foot Infections
Nada Farhat, PharmD; Daniel McClung, MD; Jerod Nagel, PharmD, BCPS
Less Is More: Surgical Procedure Time and Risk of Infections, Length-of-Stay, and Readmission across Three Distinct Surgeries
Ronak Parikh, DO; Nirav Shah, MD, MPH; Huma Saeed, M.D.; Eric Bhaimia, D.O.; Frances Lahrman, DO; Moira C. McNulty, MD; Ari Robicsek, MD; Rema Padman, PhD; Jennifer Grant, MD
Microbiology and Clinical Characteristics of Industrial Oil Burns
Devin Kelly, DO; Julie Rizzo, MD; Heather Yun, MD, FIDSA; Dana Blyth, MD
Hospital Costs for Patients with Lower Extremity Cellulitis: A Retrospective Population-Based Study
Douglas Challener, MD; Jasmine R. Marcelin, MD; Sue Visscher, Ph.D.; Larry M. Baddour, MD
  • Challener_2017.pdf (1.1 MB)
  • 255
    Sex Work, Injection Drug Use, and Abscesses: Associations in Women, But Not Men
    Deirdre Burke, MPH; Alysse Wurcel, MD, MS; David Landy, BS; Margie Skeer, ScD, MPH, MSW; Robert Heimer, PhD; Kenneth K. H. Chui, PhD; Thomas Stopka, PhD, MHS
  • IDWEEK_poster_9.22.2017.pdf (782.3 kB)
  • 256
    Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population
    Benjamin Georgiades, PharmD; Urania Rappo, MD, MS, PharmD; Pedro L. Gonzalez, MD; Jennifer S. McGregor, RPh; Jie Chen, PhD; Matthew McCarthy, MD
    More than just an Anti-Infective Agent: A Prospective Pilot Clinical Trial to Determine the Effectiveness of IV Ertapenem in Severe Hidradenitis Suppurativa
    Mayur Ramesh, MD; Rachna Jayaprakash, MD; Zachary Hanna, (DO); Kulothungan Gunasekaran, MD; Tricia Stein, MD; Odaliz Abreu-Lanfranco, MD
    High Rates of Multidrug Resistance in Diabetic Foot Infection in Detroit Area: Does It Matter?
    Oryan Henig, MD; Jason M. Pogue, PharmD; Raymond Cha, PharmD; Sorabh Dhar, MD; Umar Hayat, MD; Mahmoud Ja'Ara, Student; Paul E Kilgore, MPH, MD; Keith S. Kaye, MD, MPH
    Risk Factors and Outcomes for Bloodstream Infections (BSI) Among Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    Michael J. Rybak, PharmD, MPH, PhD; Evan J. Zasowski, PharmD, MPH, BCPS; Trang D. Trinh, PharmD, MPH, BCPS, AAHIVP; Abdalhamid M. Lagnf, MPH; Vasileios Margaritis, DDS, MSc., Ph.D.; Aaron B. Mendelsohn, M.P.H., Ph.D.
    Post-discharge antibiotic therapy in patients with acute bacterial skin and skin structure infections
    Aisling Caffrey, PhD, MS; Maya Beganovic, Pharm.D., MPH; Vrishali Lopes, MS; Kerry LaPlante, Pharm.D., FCCP, FIDSA
  • IDweek_ARC_05Sep2017.pdf (1014.8 kB)
  • 263
    Orthopedic-implant associated infection due to Gram-negative bacilli: the worrisome impact of Acinetobacter baumannii multidrug resistance in a Brazilian center
    Raquel Silva, MD; Mauro Costa Salles, MD; Roberta Matosa, Nurse; Bernardo Ayres, MD; Viviane Dias, MD; Luciana M. Caetano, M.D.
    Dynamics of S. aureus acquisition and colonization in a military training environment
    Carey Schlett, MPH; Eugene Millar, PhD; Emad Elassal, MS; Natasha Law, MA; Demond Lyles, CRA; Arile Hadley, BS; Sidney Dowlen, CRA; David Hardge, MBA; Michael Ellis, MD; Jason Bennett, MD, MSPH
    Identification of Pathogens Directly From Diabetic Foot Infections by Shotgun Metagenomic Sequencing
    James Shurko, PharmD; Steven Dallas, PhD; Bryson M. Duhon, Pharm.D.; Jordan Meckel, PharmD; Chiou-Miin Wang, PhD; Chun-Lin Lin, PhD; Nicholas Lucio, B.S.; Nameer Kirma, PhD; Grace C. Lee, PharmD, PhD
    Diabetic Foot Wounds: Which Patients are More Prone to Tetanus?
    Ferit Kuscu, MD; Behice Kurtaran, Associate Professor; Aslihan Ulu, Assistant professor; Mehtap Evran, Assistant Professor; Seza Inal, Assistant Professor; Suheyla Komur, Assistant Professor; Salih Cetiner, Associated Professor; Yesim Tasova, Professor; Hasan Salih Zeki Aksu, professor

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.